CIM
JAZZ icon

Contravisory Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Contravisory Investment Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-44
Closed -$7K – 351
2018
Q1 		$7K Sell
44
-25,614
-100% -$3.76M ﹤0.01% 278
2017
Q4 		$3.46M Sell
25,658
-3,149
-11% -$437K 1.25% 42
2017
Q3 		$4.21M Buy
+28,807
New +$4.36M 1.5% 37

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Contravisory Investment Management's JAZZ Position: Q2 2018 in Review

Contravisory Investment Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2018, closing a stake of 44 shares — an estimated $7K sold.

Contravisory Investment Management first reported a position in JAZZ in Q3 2017 and held it in 3 quarters. The position peaked at $4.21M in Q3 2017. 376 funds tracked by Wall St. Rank hold JAZZ as of Q2 2018.

  • Contravisory Investment Management reported no remaining Jazz Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Contravisory Investment Management sold 44 Jazz Pharmaceuticals shares in Q2 2018, an estimated $7K.
  • Contravisory Investment Management first reported a position in Jazz Pharmaceuticals in Q3 2017 and held it in 3 quarters.
  • Contravisory Investment Management's Jazz Pharmaceuticals position peaked at $4.21M in Q3 2017.
  • 376 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2018.

Based on Contravisory Investment Management's 13F filing for Q2 2018, filed 11 Jul 2018.